CCXI
Price
$10.27
Change
-$0.08 (-0.77%)
Updated
Oct 22 closing price
Capitalization
571.76M
Intraday BUY SELL Signals
SPRO
Price
$1.13
Change
-$0.04 (-3.42%)
Updated
Oct 22 closing price
Capitalization
65.81M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CCXI vs SPRO

CCXI vs SPRO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CCXI vs. SPRO commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CCXI is a Buy and SPRO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CCXI with price predictions
Oct 22, 2026

CCXI's Stochastic Oscillator remains in oversold zone for 11 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CCXI's RSI Oscillator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

Following a +3.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCXI advanced for three days, in 58 of 83 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCXI as a result. In 12 of 24 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 50%.

The Moving Average Convergence Divergence Histogram (MACD) for CCXI turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 6 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCXI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for CCXI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. CCXI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.131) is normal, around the industry mean (-542.660). P/E Ratio (-5.431) is within average values for comparable stocks, (117.432). Projected Growth (PEG Ratio) (2.600) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. CCXI's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCXI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.

A.I.Advisor
a Summary for SPRO with price predictions
Oct 22, 2026

SPRO sees its Stochastic Oscillator ascending out of oversold territory

On October 20, 2026, the Stochastic Oscillator for SPRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 54 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SPRO just turned positive on October 20, 2026. Looking at past instances where SPRO's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.

Following a +10.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 151 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The 10-day RSI Indicator for SPRO moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 25 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 78 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

SPRO broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SPRO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. SPRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.489) is normal, around the industry mean (2.973). P/E Ratio (8.071) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CCXI vs SPRO: Fundamental Ratings
CCXI
SPRO
OUTLOOK RATING
1..100
5465
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9848
PRICE GROWTH RATING
1..100
6464
P/E GROWTH RATING
1..100
1788
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (80) in the Pharmaceuticals Major industry is in the same range as CCXI (96) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CCXI’s over the last 12 months.

SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CCXI (100) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CCXI’s over the last 12 months.

SPRO's SMR Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for CCXI (98) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CCXI’s over the last 12 months.

SPRO's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as CCXI (64) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CCXI’s over the last 12 months.

CCXI's P/E Growth Rating (17) in the Biotechnology industry is significantly better than the same rating for SPRO (88) in the Pharmaceuticals Major industry. This means that CCXI’s stock grew significantly faster than SPRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CCXISPRO
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
65%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 18 days ago
70%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CCXI: $10.35 vs. SPRO: $1.13)
Brand notoriety: CCXI and SPRO are both not notable
CCXI represents the Financial Conglomerates, while SPRO is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: CCXI: 93% vs. SPRO: 36%
Market capitalization -- CCXI: $571.76M vs. SPRO: $65.81M
CCXI [@Financial Conglomerates] is valued at $571.76M. SPRO’s [@Biotechnology] market capitalization is $65.81M. The market cap for tickers in the [@Financial Conglomerates] industry ranges from $1.85 to $590.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Financial Conglomerates] industry is $259.22M. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CCXI’s FA Score shows that 1 FA rating(s) are green while SPRO’s FA Score has 0 green FA rating(s).

  • CCXI’s FA Score: 1 green, 4 red.
  • SPRO’s FA Score: 0 green, 5 red.
According to our system of comparison, both CCXI and SPRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CCXI’s TA Score shows that 3 TA indicator(s) are bullish while SPRO’s TA Score has 4 bullish TA indicator(s).

  • CCXI’s TA Score: 3 bullish, 4 bearish.
  • SPRO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CCXI is a better buy in the short-term than SPRO.

Price Growth

CCXI (@Financial Conglomerates) experienced а -4.43% price change this week, while SPRO (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Financial Conglomerates industry was -0.29%. For the same industry, the average monthly price growth was -0.79%, and the average quarterly price growth was +1.41%.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

SPRO is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Financial Conglomerates (-0.29% weekly)

Financial conglomerates usually encompass a wide range of financial services including (not necessarily limited to) investment banking, insurance, capital raising/underwriting, trading of financial securities, investment advisory services, wealth management of high net-worth individuals, and retail banking. Think Citigroup, American Express Company, ING Group.

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CCXI
Daily Signal:
Gain/Loss:
SPRO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CCXI and

Correlation & Price change

A.I.dvisor indicates that over the last year, CCXI has been loosely correlated with SPRO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CCXI jumps, then SPRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CCXI
1D Price
Change %
CCXI100%
-0.82%
SPRO - CCXI
48%
Loosely correlated
-3.42%
ABOS - CCXI
48%
Loosely correlated
+1.48%
ANVS - CCXI
34%
Loosely correlated
-0.15%
IPHA - CCXI
34%
Loosely correlated
-3.82%
IDYA - CCXI
34%
Loosely correlated
+1.83%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then CCXI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-3.42%
CCXI - SPRO
48%
Loosely correlated
-0.82%
ASBP - SPRO
42%
Loosely correlated
+1.47%
VYGR - SPRO
34%
Loosely correlated
-7.92%
JAGX - SPRO
34%
Loosely correlated
-5.70%
XENE - SPRO
32%
Poorly correlated
+1.53%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RENT2.370.19
+8.72%
Rent the Runway
HBCP61.421.62
+2.71%
Home Bancorp
ELAN22.690.14
+0.62%
Elanco Animal Health
VC81.70-3.13
-3.69%
Visteon Corp
KAPA0.54-0.03
-5.65%
Kairos Pharma Ltd